

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

**VOLUNTARY ANNOUNCEMENT  
UPDATE ON THE PROPOSED ISSUE OF A SHARES BY  
SHANGHAI MICROPORT ENDOVASCULAR  
MEDTECH (GROUP) CO., LTD.**

Reference is made to the announcement of the Company dated 25 July 2022 in relation to the proposed issue and placement of A Shares (the “**Proposed Issue**”) by 上海微創心脈醫療科技(集團)股份有限公司 (“Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.”) (“**EV MedTech**”).

On 13 July 2023, the Shanghai Stock Exchange (“**SSE**”) approved the Proposed Issue.

**THE PROPOSED ISSUE**

Under the Proposed Issue, EV MedTech may issue up to 21,593,444 shares (“**A Shares**”) in order to raise fund for its project development and as additional working capital. The Proposed Issue will be directed at qualified investors approved by the China Securities and Regulatory Commission (“**CSRC**”) and the SSE. The number of qualified investors for the Proposed Issue will be limited to less than 35. No A Shares will be offered to the public under the Proposed Issue.

The Proposed Issue is still subject to the approval of the CSRC.

As at the date of this announcement, the terms of the Proposed Issue, including the exact size and timing of the Proposed Issue, the issue price of the A Shares, and other terms and conditions of the Proposed Issue, have not been fixed.

The Proposed Issue will be classified as a deemed disposal by the Company of its interest in EV MedTech. The Company will publish further announcement(s) about the Proposed Issue in compliance with the requirements of Chapter 14 of the Listing Rules as and when necessary.

## INFORMATION ON EV MEDTECH

EV MedTech is principally engaged in the business of endovascular and peripheral vascular devices, and provides a range of products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular disease, aortic dissection and other endovascular related diseases. The shares of EV MedTech are listed on the science and technology innovation board of the SSE.

EV MedTech is currently owned as to 46.34% by the Group and its results are consolidated with the financial statements of the Company. It is expected that the results of EV MedTech will continue to be consolidated with the results of the Company upon completion of the Proposed Issue.

This announcement is made by the Company on a voluntary basis.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the PRC, 13 July 2023

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *For identification purpose only*